SPRING BANK TECHNOLOGIES, INC. AND MICROLOGIX BIOTECH, INC. STOCK PURCHASE AGREEMENT DECEMBER 17, 2003Stock Purchase Agreement • December 11th, 2015 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Stock Purchase Agreement (the “Agreement”) is made as of the 17th day of December 2003, by and between Spring Bank Technologies, Inc., a Massachusetts corporation having its principal office at 113 Cedar Street, Suite S-7, Milford, MA 01757, USA (the Company”) and Micrologix Biotech, Inc., a British Columbia corporation having its offices at BC Research Complex, 3650 Wesbrook Mall, Vancouver, BC, Canada V6S 2L2 (“Micrologix”).
Dr. Nezam Afdhal, M.D. Charlestown, MA 02129 Dear Nezam:Invention and Non-Disclosure Agreement • December 11th, 2015 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
On behalf of Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer:
Jonathan P. Freve Northborough, MA 01532 Dear Jon:Spring Bank Pharmaceuticals, Inc. • December 11th, 2015 • Pharmaceutical preparations
On behalf of Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), I am pleased to set forth below the terms of your continued employment with the Company, which will take effect as of the date you counter-sign this letter agreement:
Martin DriscollInvention and Non-Disclosure Agreement • December 11th, 2015 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 11th, 2015 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), made as of March 1, 2013 (the “Effective Date”), is entered into by Spring Bank Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 113 Cedar Street, Milford, Massachusetts 01757 (the “Company”), and Douglas J. Jensen having an address of 2673 Route 8, Lake Pleasant, NY 12108 (the “Executive”).
